Teva price target raised to $15 from $13 at UBS

UBS raised the firm’s price target on Teva to $15 from $13 and keeps a Buy rating on the shares. The firm expects Teva’s revenue and EBITDA guidance for FY24 to bracket $16B and $5B, respectively, and UBS sees room for EBITDA margin expansion in FY24, driven by branded revenue growth, the analyst tells investors in a research note.